Menopausal Symptoms in the Workplace and an Update on Treatment Options
Résumé
Women in midlife comprise an integral component of the Canadian workforce. The Menopause Foundation of Canada (MFC) recently completed a landmark cross-national survey of Canadian women aged 40–60. This study found that 46% of surveyed participants felt unprepared for perimenopause/menopause and that 4 in 10 participants felt their symptoms were undertreated by their healthcare provider. Fewer than 25% of respondents said their family physician proactively discussed menopause with them.
Références
Menopause Foundation of Canada. The Silence and the Stigma: Menopause in Canada (a cross-national Leger survey). 2022.
The Menopause Foundation of Canada. Menopause and Work in Canada. 2023.
Yuksel N, Evaniuk D, Huang L, et al. Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle. J Obstet Gynaecol Can. 2021 Oct;43(10):1188-1204.e1.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul;29(7):767-94.
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr 1;175(4):531.
Shufelt C, Manson J. Managing menopause by combining evidence with clinical judgment. Clin Obstet Gynecol. 2018 Sep;61(3):470-9.
Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003 Apr;237(4):474-82.
Writing Group For The Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002 Jul 17;288(3):321-33.
Hoffman SR, Governor S, Daniels K, et al. Comparative safety of conjugated estrogens/bazedoxifene versus estrogen/progestin combination hormone therapy among women in the United States: a multidatabase cohort study. Menopause. 2023 Aug;30(8):824-30.
Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Gynaecology and Fertility Group, editor. Cochrane Database Syst Rev [Internet]. 2016 Oct 12;10(10):CD008536.
Johnston S, Bouchard C, Fortier M, et al. Guideline No. 422b: Menopause and Genitourinary Health. J Obstet Gynaecol Can. 2021 Nov;43(11):1301-07.e1.
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976-92.
The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun;30(6):573-90.
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet. 2023 Apr;401(10382):1091-102.
Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar;30(3):239-46.
Goldstein S. An efficient tool for the primary care management of menopause. Can Fam Physician Med Fam Can. 2017 Apr;63(4):295-8.
Manson JE, Ames JM, Shapiro M, et al. Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society. Menopause. 2015 Mar;22(3):247-53.
